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Don’t Forget about Facilitatory Effects of
Corticosteroids on b2-Adrenoceptors in Acute Asthma
To the Editor:
We read with interest the findings of Moran and colleagues showing
equally rapid reductions in blood eosinophils with oral prednisolone
and subcutaneous benralizumab (1) in patients with poorly
controlled asthma. The authors go on to suggest that benralizuamb
might be used as an alternative to corticosteroids for the treatment
of acute exacerbations of eosinophilic asthma. Their data was not
obtained in the setting of acute severe airflow obstruction, where
airway smooth muscle constriction also plays a key role in airflow
limitation in addition to endobronchial inflammation. Pointedly,
they did not comment on whether the acute fall in eosinophils was
accompanied by a commensurate improvement in airway geometry
as FEV1. In this regard, the findings of Moran and colleagues do
not take into account the acute facilitatory effect of systemic
corticosteroids such as prednisolone on airway smooth muscle
in terms of rapid upregulation and resensitization of b2-
adrenoceptors in patients with acute asthma, especially those who
have been taking inhaled corticosteroids with long-acting b2-
agonists (2). Moreover, benralizumab exhibits antiinflammatory
activity by suppressing eosinophils alone, whereas corticosteroids
have more broad-spectrum activity on a variety of inflammatory
cells in asthma. Notably, benralizumab is also considerably
more expensive than oral prednisolone. Hence, although we
would advocate for benralizumab as a suitable long-term treatment
for reducing exacerbations in severe eosinophilic asthma, we
would not endorse its routine use for treatment in acute asthma. n
Author disclosures are available with the text of this letter at
www.atsjournals.org.
Brian Lipworth, M.D.*
Rory Chan, M.B. Ch.B.
Chris RuiWen Kuo, M.B. Ch.B.
University of Dundee
Scotland, United Kingdom
ORCID ID: 0000-0002-8140-2014 (B.L.).
*Corresponding author (e-mail: b.j.lipworth@dundee.ac.uk).
References
1. Moran AM, Ramakrishnan S, Borg CA, Connolly CM, Couillard S,
Mwasuku CM, et al. Blood eosinophil depletion with mepolizumab,
benralizumab and prednisolone in eosinophilic asthma [letter]. Am J
Respir Crit Care Med [online ahead of print] 25 Jun 2020; DOI:
10.1164/rccm.202003-0729LE.
2. Tan KS, Grove A, McLean A, Gnosspelius Y, Hall IP, Lipworth BJ.
Systemic corticosteriod rapidly reverses bronchodilator subsensitivity
induced by formoterol in asthmatic patients. Am J Respir Crit Care
Med 1997;156:28–35.
Copyright © 2020 by the American Thoracic Society
Reply to Lipworth et al.
From the Authors:
We thank Dr. Lipworth and colleagues for their interest in
our work published recently in the Journal (1). They rightly point
out that the biology of asthma attacks is more complex than
blood eosinophils alone and that corticosteroids have a wide
range of other potentially relevant antiinflammatory effects.
However, local treatment with inhaled corticosteroids (ICS) is
usually the mainstay of patients with frequent eosinophilic
exacerbations, and therefore in the great majority of patients,
the key question is what oral corticosteroids (OCS) add to
ICS in an acute attack (2) and whether this effect is seen
with benralizumab. We suggest that depletion of circulating
eosinophils is the only effect OCS are likely to have that are not
shared with ICS (3).
Because OCS are known to have severe side effects, and in
noneosinophilic exacerbations of chronic obstructive pulmonary
disease they are actually harmful (4), it would be a significant
advance to determine whether a combination of ICS and rapidly
acting anti–IL-5 treatment would cover all the benefits of OCS in
acute asthma while mitigating the harms of OCS. With respect to
this, we recently published a case report (5) that showed the
addition of benralizumab to ICS resulted in a dramatic
improvement of peak flow and FEV1 within 6 hours when given
to treat an asthma attack in a patient in whom systemic
corticosteroids were contraindicated. We believe that these
findings support the idea that systemic targets of benralizumab
that express the IL-5 receptor (such as eosinophils and basophils)
play a pivotal role in sustaining the nonbronchodilator responsive
airflow limitation seen in asthma attacks.
The use of benralizumab in acute asthma may also
provide other benefits. Treatment failure is a major issue in
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the current acute asthma treatment paradigm (6). The
longer half-life of benralizumab and the harms of systemic
corticosteroids may tip the cost–benefit assessment in favor of
benralizumab.
We agree that more work is needed before benralizumab
becomes an option for the management of asthma attacks.
Nevertheless, the rapidity of eosinophil depletion certainly makes
it an exciting prospect. We look forward to the results of our
clinical trial to examine this idea (clinicaltrials.gov ID:
NCT04098718). n
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Sherbrooke, Quebec, Canada
Christine M. Mwasuku, B.Sc., Pg.Dip.
Ian D. Pavord, D.M.
Timothy S. C. Hinks, M.D., Ph.D.
University of Oxford
Oxfordshire, United Kingdom






ORCID IDs: 0000-0002-2067-9335 (A.M.M.); 0000-0002-3003-7918 (S.R.);
0000-0002-4057-6886 (S.C.); 0000-0003-0699-2373 (T.S.C.H.);
0000-0003-1586-4998 (L.L.).
*Corresponding author (e-mail: lauri.lehtimaki@tuni.fi).
References
1. Moran AM, Ramakrishnan S, Borg CA, Connolly CM, Couillard S,
Mwasuku CM, et al. Blood eosinophil depletion with mepolizumab,
benralizumab and prednisolone in eosinophilic asthma [letter]. Am J
Respir Crit Care Med [online ahead of print] 25 Jun 2020; DOI:
10.1164/rccm.202003-0729LE.
2. Edmonds ML, Milan SJ, Camargo Jr CA, Pollack CV, Rowe BH. Early
use of inhaled corticosteroids in the emergency department treatment
of acute asthma. Cochrane Database Syst Rev 2012;2012:
CD002308.
3. Pavord ID. Oral corticosteroid-dependent asthma: current knowledge
and future needs. Curr Opin Pulm Med 2019;25:51–58.
4. Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P,
et al. Blood eosinophils to direct corticosteroid treatment of
exacerbations of chronic obstructive pulmonary disease: a
randomized placebo-controlled trial. Am J Respir Crit Care Med
2012;186:48–55.
5. Ramakrishnan S, Camp JR, Vijayakumar B, Hardinge FM, Downs ML,
Russell REK, et al. The use of benralizumab in the treatment of near-
fatal asthma: a new approach. Am J Respir Crit Care Med 2020;201:
1441–1443.
6. DiMango E, Rogers L, Reibman J, Gerald LB, Brown M, Sugar EA,
et al. Risk factors for asthma exacerbation and treatment failure
in adults and adolescents with well-controlled asthma during
continuation and step-down therapy. Ann Am Thorac Soc 2018;15:
955–961.
Copyright © 2020 by the American Thoracic Society
Erratum: COVID-19–related Genes in Sputum Cells
in Asthma: Relationship to Demographic Features
and Corticosteroids
Our article, published in the July 1, 2020, issue of the Journal (1),
contained an error in the number of healthy control subjects.
The paper reported on 330 asthma participants in the SARP-3
(NHLBI Severe Asthma Research Program-3) cohort and 79
healthy control subjects (57 recruited by the University of
California San Francisco [UCSF] Airway Clinical Research
Center and 22 recruited by SARP-3). We recently discovered
that a coding error resulted in sputum cell RNA from 47 mild
asthma patients being included in the UCSF healthy subject
group. To correct the error, we removed the 47 mild asthma
patients and reanalyzed the data. After performing the
reanalysis including the 22 healthy subjects from SARP and 10
healthy subjects from UCSF (total of 32 healthy controls)
(revised Table 1), we found that our study conclusions
remain the same. As illustrated in revised Figures 1 and 2,
sputum cell gene expression for COVID-19–related genes
(ACE2 [angiotensin-converting enzyme 2] and TMPRSS2
[transmembrane protease serine 2]) are not significantly
different in asthma and health (revised Figure 1A and 1B), and
sputum cell gene expression for ACE2 and TMPRSS2 are
significantly correlated with one another (revised Figure 2A).
The reanalysis shows that the P value for the increase in asthma
for sputum cell ICAM1 expression (a comparator/control gene)
compared with health increased from 0.005 to 0.09 (revised
Figure 1C). The main data for the paper, as originally presented
in Figures 3 and 4 and which relied on data analyses that were
restricted to the asthma cohort, do not need correction.
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